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Background: Experimental studies suggest that angiotensin II plays a central role in the pathogenesis of abdominal
aortic aneurysm. This trial aims to evaluate the efficacy of the angiotensin receptor blocker telmisartan in limiting
the progression of abdominal aortic aneurysm.
Methods/Design: Telmisartan in the management of abdominal aortic aneurysm (TEDY) is a multicentre, parallel-
design, randomised, double-blind, placebo-controlled trial with an intention-to-treat analysis. We aim to randomly
assign 300 participants with small abdominal aortic aneurysm to either 40 mg of telmisartan or identical placebo
and follow patients over 2 years. The primary endpoint will be abdominal aortic aneurysm growth as measured by
1) maximum infra-renal aortic volume on computed tomographic angiography, 2) maximum orthogonal diameter
on computed tomographic angiography, and 3) maximum diameter on ultrasound. Secondary endpoints include
change in resting brachial blood pressure, abdominal aortic aneurysm biomarker profile and health-related quality
of life. TEDY is an international collaboration conducted from major vascular centres in Australia, the United States
and the Netherlands.
Discussion: Currently, no medication has been convincingly demonstrated to limit abdominal aortic aneurysm
progression. TEDY will examine the potential of a promising treatment strategy for patients with small abdominal
aortic aneurysms.
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Abdominal aortic aneurysm (AAA) is a major contributor
to mortality in western countries, responsible for over
10,000 annual deaths in the USA and costing the health-
care system more than $3 billion per annum [1, 2]. Over
the last decade a number of advances have been made to
the management of AAA including the introduction of
screening programs designed to identify AAAs before they
rupture and the development of sophisticated minimally
invasive techniques to repair large AAAs [3, 4]. The intro-
duction of targeted AAA ultrasound screening programs
in a number of countries, such as the United States, the
United Kingdom and Sweden, is expected to reduce AAA-
related mortality. Individuals found to have large AAAs
(infra-renal aortic diameter >55 mm) are usually consid-
ered for elective surgical repair to prevent potentially fatal
AAA rupture. However 90 % of AAAs detected through
screening are <55 mm in diameter (small AAAs), and
these carry a low risk of rupture [5, 6]. Four trials have
suggested that early elective open or endovascular repair
does not reduce mortality for patients with AAAs measur-
ing 40 to 55 mm in diameter [7]. Current guidelines there-
fore advocate that patients with small AAAs be managed
conservatively with surveillance comprising repeated im-
aging and consultations [8]. On average, small AAAs ex-
pand 1 to 3 mm per year and up to 70 % of patients will
eventually require surgery [9–11]. This current practice of
simply monitoring small AAAs is associated with reduced
health-related quality of life, possibly due to patients’ con-
cerns that no active treatment is being undertaken [12].
Effective drug therapies that prevent or limit AAA
growth may improve health-related quality of life, reduce
the need for surgery and prevent mortality in patients
unsuitable for AAA repair. There is limited evidence
suggesting that the control of atherogenic risk factors
alone slows AAA progression [13]. However such treat-
ment is still advised as these individuals are at high risk
of acute cardiovascular events [14]. A number of small
randomised controlled trials have been conducted in
humans in an attempt to discover a drug that limits
AAA growth [15, 16]. Only two published studies, using
the β-blocker propranolol and the antibiotic doxycycline,
included more than 200 patients, and neither study re-
ported a benefit of the medication tested [17, 18]. Drugs
shown to slow AAA progression in animal models and
observational human studies include statins, macrolides,
cyclooxygenase inhibitors and developmental agents
such as c-Jun N-terminal kinase inhibitors [19–23].
While statins are well tolerated, they are already indi-
cated and prescribed in most patients with AAAs and
therefore difficult to assess for their efficacy in limiting
AAA progression [24, 25]. A potential drug to be trialled
for AAA ideally requires a number of important charac-
teristics including evidence to support its benefit, a goodsafety profile from phase II studies or use of the medi-
cation in related conditions, and likelihood of good
compliance.
There is a large body of evidence suggesting that
angiotensin II plays a critical role in AAA formation,
progression and rupture [26]. Infusion of angiotensin II
via a subcutaneous osmotic pump constitutes a com-
monly applied mouse model of aortic aneurysm, utilized
in hundreds of studies to date [27]. Such angiotensin
II-induced AAAs have some features comparable to
human AAA, including a similar gene expression profile
on microarray analysis; marked inflammatory focus;
associated thrombus; and predilection for males and
sites of atherosclerosis [28]. Angiotensin II activates the
angiotensin II receptor type 1 (AT1) to promote a series
of molecular changes implicated in AAA formation in-
cluding up-regulation of pro-inflammatory cytokines
and proteins, such as osteopontin (OPN), osteoproteg-
erin (OPG), transforming growth factor-beta1 (TGF-β1),
and matrix metalloproteinase-9 (MMP-9) [29–31]. The
reduction in ascending aortic diameter in patients with
Marfan syndrome after 6 months therapy with the
angiotensin converting enzyme inhibitor, perindopril,
supports a clinical rationale for renin angiotensin system
inhibition in humans [32]. The 3 to 7 mm reduction in
aortic diameter in this trial was also associated with re-
duction in circulating TGF-β and MMP levels [33].
Given the current evidence suggesting a central role of
angiotensin II in the pathogenesis of AAA, the use of
AT1 blockers to potentially slow AAA progression has
generated considerable interest. Telmisartan is a potent,
long-acting AT1 blocker classically indicated for essen-
tial hypertension, heart failure and renal failure. We
hypothesise that telmisartan will reduce AAA growth by
down-regulation of the AT1 pathway. Telmisartan also
has PPARγ agonist activity that is greater than other
AT1 blockers [34, 35]. Evidence has accumulated show-
ing PPARγ ligation to inhibit angiotensin II-mediated
up-regulation of OPN, OPG, MMP-9 and TGF-β1,
which are implicated in AAA [36–39]. In animal models
PPARγ agonists limit AAA development, progression
and rupture [36, 38, 40]. The combination of AT1 block-
ade and PPARγ ligation could be very effective in limit-
ing AAA expansion in humans.
Inhibition of AT1 could have benefit over angiotensin-
converting enzyme (ACE) inhibition for several reasons:
(i) ACE inhibition, unlike AT1 blockade, only indirectly
inhibits the angiotensin pathway; (ii) a number of non-
ACE angiotensin II producing enzymes have been identi-
fied in AAA biopsies, suggesting that ACE inhibition may
only partially inhibit the effects of angiotensin II [41, 42];
(iii) part of the blood pressure-lowering effect of ACE in-
hibitors is attributable to an increase in circulating kinins,
which have unknown effects on AAA [43]; and (iv) AT1
Table 1 Patient eligibility criteria
Inclusion criteria
• Written informed consent
• Infra-renal AAA with maximum orthogonal diameter of ≥35 mm and
≤49 mm on CTA or ultrasound
• No current indication for AAA repair, or expectation that this will be
revised in 12 months
• Likely to comply with treatment over 24 months, including seven visits
to study centre
Exclusion criteria
• Currently taking or likely to start taking an AT1 blocker
• Currently taking or likely to start taking an ACE inhibitor
• Previous abdominal aortic surgery
• Contraindication to telmisartan:
o Renal impairment: creatinine >1.5 x ULN
o Known renal artery stenosis >70 % of one or both renal arteries
o Chronic liver disease (that is, cirrhosis or hepatitis) or abnormal liver
function (that is, ALT > 1.5 x ULN)
o Electrolyte imbalance
o Active gout
AAA, abdominal aortic aneurysm; ACE, angiotensin converting enzyme; ALT,
alanine transaminase; AT1, angiotensin II receptor type 1; CTA, computed
tomographic angiography; ULN, upper limit of normal
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compared to ACE inhibitors in some studies [44].
Telmisartan has been shown to inhibit AAA in three
different animal model studies [45–47]. AT1 blocker
prescription has also been associated with reduced AAA
progression in one surveillance study involving 1,269
patients with small AAA [48]. To date, no randomised
trials have been conducted to examine the effect of an
AT1 inhibitor on AAA progression. This trial seeks to
evaluate the efficacy of telmisartan in limiting AAA
expansion.
Methods/Design
Study design
Telmisartan in the management of abdominal aortic
aneurysm (TEDY) is a parallel-design, randomised,
double-blind, placebo-controlled trial to assess whether
treatment with telmisartan for 2 years will reduce the
rate of AAA expansion. The TEDY trial plans to enrol
300 participants with small AAA, defined by a max-
imum orthogonal infra-renal aortic diameter of ≥35 and
≤49 mm on computed tomographic angiography (CTA)
or ultrasound. In order to explicitly assess the impact of
AT1 blockade on AAA expansion, TEDY will only in-
clude individuals who have no current or planned usage
of AT1 blockers or ACE inhibitors. TEDY will not in-
clude individuals with an existing indication for AAA re-
pair (according to the treating physician) or expectation
that this will be revised within one year. Furthermore,
participants will only be included if they have a high
likelihood of treatment compliance for 24 months ac-
cording to their supervising physician. Additional exclu-
sion criteria include contraindications to telmisartan and
previous abdominal aortic surgery. A full list of inclusion
and exclusion criteria is given in Table 1.
Randomisation and follow-up
The overall design of the TEDY trial is shown in Fig. 1.
At the initial visit, individuals will be considered for in-
clusion in the trial (Table 1) and if eligible, informed
consent will be sought. Individuals will undergo a short
health survey, clinical examination by a medical officer,
resting brachial blood pressure, resting ankle-brachial
index, and collection of fasting blood samples for
analysis of lipid profile, blood glucose, inflammatory
markers, AAA biomarkers, liver function and renal
function. An additional blood sample will be stored for
future genetic, protein and lipidomic analyses. A base-
line CTA and ultrasound will be obtained for detailed
measurements of the AAA.
Eligible participants who have provided written in-
formed consent will return for a randomisation visit,
during which they will be allocated to either telmisartan
(40 mg od daily) or matching placebo (once daily) for 24months. Patients will be randomised by a blinded health
professional through the secure trial website, coor-
dinated by an independent trial centre. Treatment
allocation will be determined by a computer-generated
random number sequence that is stratified by study site
and initial aortic diameter (35 to 39 mm, 40 to 44 mm,
and 45 to 49 mm). Random number sequences will cor-
respond to serial numbers on concealed study packaging.
Only the trial drug centre and the Data and Safety
Monitoring Board (DSMB) will know the identity of
pre-packaged drugs. The Stanford study centre will
utilize an independent randomization procedure imple-
mented locally, whereby ID numbers are randomly
allocated to the two study groups using randomization
software (www.tufts.edu/~gdallal/randomize.htm). The
resultant randomization key will be provided to the on-
site pharmacy, which dispenses study medication to par-
ticipants according to the condition assignment pre-
scribed by the key.
Following randomisation, participants will receive their
allocated study medication and subsequent instruction
on the dosing regimen. Individuals will be contacted by
phone 2 weeks after randomisation and asked about
adherence to study treatment and known medication
side effects. Phone consultations will be repeated at 9,
15 and 21 months. Follow-up visits will occur at 3, 6, 12,
18 and 24 months, during which the occurrence of trial
endpoints and adverse events will be appraised. Partici-
pants will receive ongoing health questionnaires, clinical
Fig. 1 Design of the Telmisartan in the management of abdominal aortic aneurysm (TEDY) Trial
Table 2 Visit schedule
Study time points (months)
0 0 ½ 3 6 9 12 15 18 21 24
Assessment Visit 1 Visit 2 Phone Call Visit 3 Visit 4 Phone Call Visit 5 Phone Call Visit 6 Phone Call Visit 7
Consent x
Enrolment/randomisation x
CT angiography x xa x
Ultrasound x x x x x
Blood test (safety) x x x x
Blood collection (study) x x x x x
Resting brachial BP x x x x x x
SF-36 questionnaire x x x
Physical assessments x± x x x x x
Medical examination x x x x
Resting ABI x x x
Collection of study medication x x x x
Return of study medication x x x x
Event outcomes x x x x x
AE and compliance check x x x x x x x x x
Physical assessments include: resting BP, resting heart rate, weight, hip and waist measurements, ±indicates an additional assessment of height. ABI, ankle
brachial-index; AE, adverse effects; BP, blood pressure; CT, computed tomography
aThe Leiden and Stanford study centres will not perform 12-month CTAs due to local ethics regulations. The Stanford centre will utilize a slightly different study
schedule. In place of the 2-week phone call and 3-month visit, participants will attend for a safety visit at 1 month for assessment of adherence to study treatment
and medication side effects. Study medications will be prescribed at 3-month intervals with AE and compliance checks at 3, 9, 15 and 21 months
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Table 2. All participants, including those in whom allo-
cated medication is discontinued, will be invited to
follow up for the duration of the study in the absence of
AAA repair. Final follow-up will occur at 24 months
after randomisation, at which point the participant will
discontinue the prescribed medication.
Endpoints
The trial primary endpoint will be the difference in AAA
growth between the intervention and control groups
over 24 months. AAA growth will be assessed by 1)
maximum infra-renal aortic volume on CTA, 2) max-
imum orthogonal diameter on CTA, and 3) maximum
diameter on ultrasound. Infra-renal aortic volume can
be measured in a reproducible way and changes in it ap-
pear to provide a more sensitive means to assess AAA
growth [49]. It is expected that a number of participants
may not receive a CTA at 24 months due to drop-out,
for example due to requirement for AAA surgery. We
therefore have also included ultrasound measured AAA
growth as a primary endpoint since ultrasound assess-
ments will be performed every 6 months.
CTA will be obtained at entry, 12 and 24 months de-
pending on local ethics guidelines (CTA at entry and 24
months only for Stanford and Leiden study centres).
Assessment of infra-renal aortic volume will be per-
formed according to a previously established protocol at
the main study centre (mean inter-observer coefficient
of variation = 2.7 %) [49]. The total volume of the infra-
renal aorta, including the aortic wall and lumen, will be
estimated using a semi-automated program that we have
previously established to be reproducible [49]. In short,
axial regions of interest are drawn around the aorta from
the slice inferior to the origin of the lowest renal artery
to the slice superior to the bifurcation of the aorta. The
areas of these regions of interest are summated using
CT analysis software to yield an overall volume. The
maximum orthogonal AAA diameter on CTA is a meas-
urement of infra-renal aortic diameter perpendicular to
the lumen, devised to avoid over-estimation of tortuous
AAAs. We have previously reported a reproducible
protocol to measure orthogonal aortic diameter (mean
inter-observer coefficient of variation = 3.5 %) [50].
Initially, seeds are placed in the centre of the infra-renal
aorta from the renal arteries to the aortic bifurcation.
Curved multi-planar reconstruction is then used to
reconstruct the aorta perpendicular to its axis. The
reconstructed aorta is subsequently scouted to find the
region of maximum diameter, taking many measure-
ments. The largest diameter is taken to be the maximum
orthogonal diameter.
Ultrasound measurements will be undertaken at entry,
6, 12, 18 and 24 months. Maximum anteroposterior andtransverse infra-renal aortic diameter will be measured by
experienced sonographers using a 3.75-MHz transducer
and ultrasound machines present in vascular laboratories
of each centre. Diameters will be measured in the plane of
the aorta with callipers placed on the outer part of the
aortic wall. The largest external anterior-posterior and
transverse AAA diameters will be recorded. The location
at which the maximum diameter is measured will always
be within the infra-renal aorta but will be selected based
on the maximum diameter not particular location within
this artery segment. The intra-observer reproducibility of
ultrasound measurements has been assessed at major
participating centres and shown to be good (coefficient of
repeatability ≤1.6 mm for four reporting centres) [18, 31].
Central analysis of both CTA and ultrasound images will
be performed at the study centre.
Secondary endpoints include change in resting bra-
chial blood pressure, AAA biomarker profile, and
health-related quality of life. Resting brachial blood
pressure will be measured at entry, 3, 6, 12, 18 and 24
months. Three blood pressure measurements will be re-
corded at 3-minute intervals, with the average blood
pressure used as the representative value. Blood will be
taken at entry, 6, 12, 18 and 24 months to assess
changes in circulating AAA biomarkers. The AAA bio-
marker panel will include OPN, OPG, D-dimer, TGF-β1
and MMP-9, and will be measured centrally. These cir-
culating proteins have been selected based on extensive
evidence suggesting that they have a central role in
AAA pathology [39, 51]. Health-related quality of life
will be assessed by the Short Form-36 (SF-36) question-
naire collected at entry, 12 and 24 months. The SF-36
has previously been validated for use in elderly patients
with vascular disease [52, 53].
Additional outcome data recorded will include re-
quirement for AAA repair surgery as determined by the
treating vascular surgeon, AAA rupture, all-cause mortal-
ity, acute cardiovascular events, withdrawal from study
medication, drug safety and changes in background medi-
cation. Medication compliance will be assessed by hand-
counting of pills during scheduled visits.
Sample size and power calculations
At present there is insufficient preliminary data demon-
strating an accurate effect size of AT1 blockers on AAA
growth. In line with other AAA drug trials, we estimated
our sample size based on a clinically relevant reduction of
30 % in annual AAA growth [18]. Given local AAA growth
rates (mean = 1.20 mm/y, standard deviation = 1.16)
applicable to the study population, we calculated an
effect size d = 0.36 [54]. Accordingly, based on t-test
analysis, this study requires 126 participants per group
(252 in total, power = 80 %, α = 0.05) to detect the
hypothesised reductions in AAA growth. Taking into
Morris et al. Trials  (2015) 16:274 Page 6 of 10account a 24-month drop-out rate of approximately 20 %,
we plan to recruit 300 patients.
Study organization
The TEDY trial has been developed through an inter-
national collaboration of experts in AAA biology,
clinical management of AAA, aortic imaging and drug
trials. TEDY is a multi-centre study conducted from
major vascular centres in Australia, The Netherlands
and the USA. The study steering committee comprises
senior vascular investigators from the centres involved
and experts in drug trials and data analysis (Appendix).
This will be the main policy and decision-making com-
mittee for the study and will meet by teleconference.
Currently, there are nine study centres in total, seven in
Australia, one in Leiden, Netherlands, and one in
Stanford, California, USA. The Stanford study centre is
sponsored by Medtronic Inc. (Santa Rosa, CA) and will
utilise independent randomisation, medication conceal-
ment and imaging analysis. The core imaging and
biomarker laboratories are located at the Vascular Biology
Unit, Queensland Research Centre for Peripheral Vascular
Disease, James Cook University, Townsville Australia,
and the Veteran’s Administration Palo Alto Health Care
System, USA. The web-based randomisation database
will be managed by the Monash Clinical Trials Centre,
Melbourne Australia, with an independent randomisa-
tion centre at Stanford University. The Baker IDI Heart
and Diabetes Institute will coordinate medication con-
cealment and packaging for Australian centres. The
Leiden study centre will coordinate medication conceal-
ment locally for convenience. An independent DSMB
will review all adverse events and conduct an interim
analysis.
Data handling
Trial documentation including design, eligibility criteria,
protocols and case report forms (CRF) will be shared
electronically with participating study centres. The on-
line clinical trial portal will house the central web-based
randomisation system (https://ccre.med.monash.edu.au/
TedyRand/). Data recorded on printed CRFs will be
faxed or scanned to the trial coordinating centre where
it will be entered centrally and examined for data qual-
ity. All participating centres have received local ethics
approval and the study is being conducted in accordance
with the Declaration of Helsinki. The TEDY trial is regis-
tered at www.anzctr.org.au: ACTRN12611000931976. The
Stanford arm of the trial is registered at www.clinicaltrials.gov
ID: NCT01683084.
Safety
Previous large randomised control trials have shown
telmisartan to have a good safety record [55, 56]. TheTRANSCEND trial demonstrated negligible side effects
for telmisartan (80 mg od daily) in approximately 6,000
individuals with cardiovascular disease [55]. These find-
ings suggest that telmisartan (40 mg od daily) should be
well tolerated by the majority of patients eligible for the
TEDY trial. Participant safety will be assessed on all
visits and phone calls. Detailed safety assessment will
occur at 3, 12 and 24 months and will involve a targeted
medical history, physical examination of heart rate and
brachial blood pressure, laboratory parameters including
serum chemistry (liver function tests, glucose, creatinine,
sodium, potassium, chloride) and haematology (haemo-
globin, differential white blood cell count and platelet
count), and adverse event reporting via report forms
provided to study centres. Participant safety will also be
assessed by phone calls occurring at 2 weeks, 9 months,
15 months and 21 months. Adverse events may com-
prise shortness of breath, wheeze, rash, dizziness and
fatigue. Possible side effects of the medication include
back pain, diarrhoea, respiratory tract infection and
sinus inflammation. In line with other medication trials,
serious adverse events (SAEs) will be defined as death,
requirement for in-patient hospital treatment and per-
sistent or significant disability.
The DSMB will consist of an independent epidemiolo-
gist, vascular surgeon and statistician; and will meet to
assess all adverse events. In particular, the DSMB will
concentrate on AAA-related events such as sudden
death due to AAA rupture, as well as adverse events
related to study medication. Expected AAA rupture rates
for small AAAs are approximately 1 to 2 % per year
based on published data [9, 10]. Rupture rates greater
than this will be considered to be a cause for concern. In
this instance consideration will be given to assessment
of all other outcome data from the study. AAA growth
will be compared between placebo and telmisartan
groups using this data. The final decision to stop the
study will take into account AAA ruptures, AAA growth
data and any other serious complications. Following
their assessment, the DSMB would report their recom-
mendation to the steering committee. One formal in-
terim analysis will be undertaken when 60 % of
participants have been followed-up for 24 months. Based
on all available data at the time of the interim analysis,
the difference in growth at 24 months of follow-up will
be estimated and tested.
Statistical analysis
The principal analysis of primary and secondary end-
points will be based on intention to treat at the time of
randomisation. All patients who meet the eligibility cri-
teria, provide written informed consent and are enrolled
in the study will be included in the primary analysis,
regardless of adherence to treatment medication. The
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ing the distribution of recognized determinants of AAA
progression and also background medication use prior
to the study between the treatment and control groups.
The primary efficacy parameter is the between treat-
ment groups difference in mean growth in AAA over 2
years as estimated by the maximum AAA volume on
CTA, maximum orthogonal diameter on CTA, and max-
imum diameter on ultrasound. If there were to be no
drop-outs, the observed mean progression over 2 years
would be compared and tested using a two-sample t-test.
However, it is expected that a non-negligible proportion of
patients will drop out before 2 years due to aneurysm
repair. Aneurysm growth will therefore be analysed by a
linear mixed model, specifying zero difference between
treatment groups at baseline. The model will have up to
11 repeated dependent measurements: three CTA volume
measurements, three CTA diameter measurements, and
five ultrasound measurements.
The fixed part of the model will contain the following
covariates: Time for CTA measurements as a categorical,
time for ultrasound measurements as a categorical,
treatment, interaction between treatment and CTA time,
and interaction between treatment and ultrasound time.
The covariance part of the model will constitute a linear
covariance matrix containing the following parameters:
Variance of CTA measurements, variance of ultrasound
measurements and covariance parameters. Without ref-
erence to the fixed part of the model, the goodness of fit
of the assumed covariance model will be investigated. If
necessary, the model will be extended with additional
terms. The analysis will be performed using the PROC
MIXED procedure on SAS (Cary, North Carolina),
which is capable of fitting arbitrary linear covariance
matrices. The main null hypothesis that will be tested is
based on the treatment effect as estimated by this model
at 24 months on CTA and ultrasound measurements.
It is possible that participants randomised to telmisar-
tan may have a small reduction in blood pressure. In the
event that the control group are more frequently receiv-
ing other blood pressure modifying medications at the
completion of the trial, post-hoc analyses will be con-
ducted with appropriate adjustment for these confound-
ing factors.
The stopping boundaries are based on the alpha and
beta spending function theory and the stopping rule
preserves the overall probability of 0.05 of rejecting the
null hypothesis in favour of telmisartan while the null
hypothesis is true [57]. The stopping rule is flexible in
the sense that the actual time of the interim analyses
may deviate from the scheduled time and that more
interim analyses may be inserted. The stopping rule is
designed using SAS PROC SEQDESIGN. We have
chosen a gamma cumulative spending function withgamma parameter equal to −5 for alpha and −7 for beta.
These choices lead to conservative stopping boundaries,
such that the trial will stop for superiority only if the
evidence for a favourable telmisartan effect is very strong
and the trial will stop for futility only if the interim ana-
lysis suggests it very unlikely that a significant telmisar-
tan effect will be found at the end of the trial. At the
interim analysis, the trial will stop for superiority if the
one-sided P value in favour of telmisartan is smaller than
0.0032. The trial will stop for futility if the one-sided
P value is larger than 0.5.
Discussion
A number of randomised control trials have been under-
taken to examine the efficacy of AAA growth-limiting
drugs. To date, no medication has demonstrated efficacy
in reducing AAA growth convincingly. TEDY is the first
clinical trial to address whether AT1 blockers can limit
AAA progression in humans. Another trial is assessing
the influence of an ACE inhibitor on AAA progression
[58]; however, the mode of action of AT1 blockers and
ACE inhibitors are not analogous. A large population
study reported that ACE inhibitor prescription was asso-
ciated with less likelihood of presenting with a ruptured
AAA [59]. Another study, however, found ACE inhibitor
prescription to be associated with increased AAA expan-
sion [60]. There is preliminary evidence from animal
studies, observational studies in humans, and rando-
mised trials on Marfan’s disease to suggest that AT1
blockade will limit AAA growth in humans [32, 45–48].
If successful, TEDY will confirm the central role of the
angiotensin pathway in AAA pathogenesis, and provide
the first growth limiting drug for secondary prevention
of AAA.
Trial status
Participants are currently being recruited.
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